Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30958109,Maximum concentrations,"Maximum concentrations of levamisole were found on the first day after the administration (531.1 μg/kg in liver, 164.3 μg/kg in egg yolk, 130.7 μg/kg in kidney, 78.0 μg/kg in breast muscle, 70.7 μg/kg in thigh muscle and 64.0 μg/kg in egg white), after which there is a decline.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),[μg] / [kg],531.1,13806,DB00848,Levamisole
,30958109,Maximum concentrations,"Maximum concentrations of levamisole were found on the first day after the administration (531.1 μg/kg in liver, 164.3 μg/kg in egg yolk, 130.7 μg/kg in kidney, 78.0 μg/kg in breast muscle, 70.7 μg/kg in thigh muscle and 64.0 μg/kg in egg white), after which there is a decline.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),[μg] / [kg],164.3,13807,DB00848,Levamisole
,30958109,Maximum concentrations,"Maximum concentrations of levamisole were found on the first day after the administration (531.1 μg/kg in liver, 164.3 μg/kg in egg yolk, 130.7 μg/kg in kidney, 78.0 μg/kg in breast muscle, 70.7 μg/kg in thigh muscle and 64.0 μg/kg in egg white), after which there is a decline.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),[μg] / [kg],130.7,13808,DB00848,Levamisole
,30958109,Maximum concentrations,"Maximum concentrations of levamisole were found on the first day after the administration (531.1 μg/kg in liver, 164.3 μg/kg in egg yolk, 130.7 μg/kg in kidney, 78.0 μg/kg in breast muscle, 70.7 μg/kg in thigh muscle and 64.0 μg/kg in egg white), after which there is a decline.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),[μg] / [kg],78.0,13809,DB00848,Levamisole
,30958109,Maximum concentrations,"Maximum concentrations of levamisole were found on the first day after the administration (531.1 μg/kg in liver, 164.3 μg/kg in egg yolk, 130.7 μg/kg in kidney, 78.0 μg/kg in breast muscle, 70.7 μg/kg in thigh muscle and 64.0 μg/kg in egg white), after which there is a decline.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),[μg] / [kg],70.7,13810,DB00848,Levamisole
,30958109,Maximum concentrations,"Maximum concentrations of levamisole were found on the first day after the administration (531.1 μg/kg in liver, 164.3 μg/kg in egg yolk, 130.7 μg/kg in kidney, 78.0 μg/kg in breast muscle, 70.7 μg/kg in thigh muscle and 64.0 μg/kg in egg white), after which there is a decline.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),[μg] / [kg],64.0,13811,DB00848,Levamisole
,30958109,half-life,"The compound was rapidly eliminated from eggs, with a half-life of 1.3 days.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,1.3,13812,DB00848,Levamisole
,30958109,Elimination,"Elimination appeared to be slower in thigh muscle (3.5 days), breast muscle (3.4 days) and liver (3.3 days).","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,3.5,13813,DB00848,Levamisole
,30958109,Elimination,"Elimination appeared to be slower in thigh muscle (3.5 days), breast muscle (3.4 days) and liver (3.3 days).","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,3.4,13814,DB00848,Levamisole
,30958109,Elimination,"Elimination appeared to be slower in thigh muscle (3.5 days), breast muscle (3.4 days) and liver (3.3 days).","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,3.3,13815,DB00848,Levamisole
,30958109,withdrawal periods,"According to this experiment, the levamisole withdrawal periods calculated for eggs, liver, kidney, breast muscle and thigh muscle in laying hens were 14.1, 6.1, >4.0, 14.5 and 13.0 days, respectively.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,14.1,13816,DB00848,Levamisole
,30958109,withdrawal periods,"According to this experiment, the levamisole withdrawal periods calculated for eggs, liver, kidney, breast muscle and thigh muscle in laying hens were 14.1, 6.1, >4.0, 14.5 and 13.0 days, respectively.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,6.1,13817,DB00848,Levamisole
,30958109,withdrawal periods,"According to this experiment, the levamisole withdrawal periods calculated for eggs, liver, kidney, breast muscle and thigh muscle in laying hens were 14.1, 6.1, >4.0, 14.5 and 13.0 days, respectively.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,>,13818,DB00848,Levamisole
,30958109,withdrawal periods,"According to this experiment, the levamisole withdrawal periods calculated for eggs, liver, kidney, breast muscle and thigh muscle in laying hens were 14.1, 6.1, >4.0, 14.5 and 13.0 days, respectively.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,4.0,13819,DB00848,Levamisole
,30958109,withdrawal periods,"According to this experiment, the levamisole withdrawal periods calculated for eggs, liver, kidney, breast muscle and thigh muscle in laying hens were 14.1, 6.1, >4.0, 14.5 and 13.0 days, respectively.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,14.5,13820,DB00848,Levamisole
,30958109,withdrawal periods,"According to this experiment, the levamisole withdrawal periods calculated for eggs, liver, kidney, breast muscle and thigh muscle in laying hens were 14.1, 6.1, >4.0, 14.5 and 13.0 days, respectively.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,13.0,13821,DB00848,Levamisole
,30958109,time,"The longest time for levamisole residues to be completely released from tissues was seen in liver samples (37.4 days), followed by thigh muscle, breast muscle and kidney.","Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,37.4,13822,DB00848,Levamisole
,30958109,Elimination,Elimination from eggs was fastest (16.4 days for levamisole residues to drop below the method quantification limit).,"Distribution and elimination of levamisole in eggs and tissues after oral administration to laying hens, determined by LC-MS/MS. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30958109/),d,16.4,13823,DB00848,Levamisole
,16031951,compartmental volume of distribution at steady state (Vss),"The mean values for the compartmental volume of distribution at steady state (Vss) were 2.034 +/- 0.23 I, 2.347 +/- 0.720 and 2.001 +/- 0.367 I/kg for each dose, respectively, and values obtained using the statistical moment theory were 2.141 +/- 0.269,2.390 +/- 0.536 and 2.140 +/- 0.345 l/kg for each dose, respectively.",Pharmacokinetics of levamisole in sheep after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16031951/),i,2.034,13924,DB00848,Levamisole
,16031951,compartmental volume of distribution at steady state (Vss),"The mean values for the compartmental volume of distribution at steady state (Vss) were 2.034 +/- 0.23 I, 2.347 +/- 0.720 and 2.001 +/- 0.367 I/kg for each dose, respectively, and values obtained using the statistical moment theory were 2.141 +/- 0.269,2.390 +/- 0.536 and 2.140 +/- 0.345 l/kg for each dose, respectively.",Pharmacokinetics of levamisole in sheep after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16031951/),[i] / [kg],2.347,13925,DB00848,Levamisole
,16031951,compartmental volume of distribution at steady state (Vss),"The mean values for the compartmental volume of distribution at steady state (Vss) were 2.034 +/- 0.23 I, 2.347 +/- 0.720 and 2.001 +/- 0.367 I/kg for each dose, respectively, and values obtained using the statistical moment theory were 2.141 +/- 0.269,2.390 +/- 0.536 and 2.140 +/- 0.345 l/kg for each dose, respectively.",Pharmacokinetics of levamisole in sheep after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16031951/),[i] / [kg],2.001,13926,DB00848,Levamisole
,16031951,compartmental volume of distribution at steady state (Vss),"The mean values for the compartmental volume of distribution at steady state (Vss) were 2.034 +/- 0.23 I, 2.347 +/- 0.720 and 2.001 +/- 0.367 I/kg for each dose, respectively, and values obtained using the statistical moment theory were 2.141 +/- 0.269,2.390 +/- 0.536 and 2.140 +/- 0.345 l/kg for each dose, respectively.",Pharmacokinetics of levamisole in sheep after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16031951/),[l] / [kg],2.141,13927,DB00848,Levamisole
,16031951,compartmental volume of distribution at steady state (Vss),"The mean values for the compartmental volume of distribution at steady state (Vss) were 2.034 +/- 0.23 I, 2.347 +/- 0.720 and 2.001 +/- 0.367 I/kg for each dose, respectively, and values obtained using the statistical moment theory were 2.141 +/- 0.269,2.390 +/- 0.536 and 2.140 +/- 0.345 l/kg for each dose, respectively.",Pharmacokinetics of levamisole in sheep after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16031951/),[l] / [kg],2.390,13928,DB00848,Levamisole
,16031951,compartmental volume of distribution at steady state (Vss),"The mean values for the compartmental volume of distribution at steady state (Vss) were 2.034 +/- 0.23 I, 2.347 +/- 0.720 and 2.001 +/- 0.367 I/kg for each dose, respectively, and values obtained using the statistical moment theory were 2.141 +/- 0.269,2.390 +/- 0.536 and 2.140 +/- 0.345 l/kg for each dose, respectively.",Pharmacokinetics of levamisole in sheep after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16031951/),[l] / [kg],2.140,13929,DB00848,Levamisole
,3212292,half-time of elimination,"For the remaining five, intravenous data fitted a one compartment model with first order elimination and a mean half-time of elimination of 1.8 hours.",Levamisole pharmacokinetics and bioavailability in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3212292/),h,1.8,16937,DB00848,Levamisole
,3212292,fraction absorbed (F),In fasting dogs drug absorption from the gut was rapid and the mean fraction absorbed (F) was 0.64.,Levamisole pharmacokinetics and bioavailability in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3212292/),,0.64,16938,DB00848,Levamisole
,33915293,oral bioavailability,"In the single-dose administration, quantified LVM concentrations were dose-dependent and the oral bioavailability was in the range of 43.2-49.6%.",Pharmacokinetics and pharmacodynamics of single and multiple-dose levamisole in belugas (Huso huso): Main focus on immunity responses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915293/),%,43.2-49.6,17295,DB00848,Levamisole
,33915293,peak plasma concentration at the steady state,"In the multiple-dose administration, the peak plasma concentration at the steady state was 45.2 mg/ml, and accumulation ratio was calculated as 3.6.",Pharmacokinetics and pharmacodynamics of single and multiple-dose levamisole in belugas (Huso huso): Main focus on immunity responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915293/),[mg] / [ml],45.2,17296,DB00848,Levamisole
,33915293,accumulation ratio,"In the multiple-dose administration, the peak plasma concentration at the steady state was 45.2 mg/ml, and accumulation ratio was calculated as 3.6.",Pharmacokinetics and pharmacodynamics of single and multiple-dose levamisole in belugas (Huso huso): Main focus on immunity responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915293/),,3.6,17297,DB00848,Levamisole
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,52,24392,DB00848,Levamisole
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,72,24393,DB00848,Levamisole
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,80,24394,DB00848,Levamisole
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,87,24395,DB00848,Levamisole
,27474036,absorption rates,The absorption rates for levamisole (0.71 ± 0.32 h-1) and abamectin (0.24 ± 0.08 day-1) from the MCMDG-based formulation were considerably slower than those of other studies conducted on the commercial products.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),1/[h],0.71,40236,DB00848,Levamisole
,27474036,absorption rates,The absorption rates for levamisole (0.71 ± 0.32 h-1) and abamectin (0.24 ± 0.08 day-1) from the MCMDG-based formulation were considerably slower than those of other studies conducted on the commercial products.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),1/[d],0.24,40237,DB00848,Levamisole
,27474036,tmax,The tmax was delayed for levamisole (2.20 ± 0.45 h) and abamectin (4.20 ± 1.64 days) compared with those in published studies.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),h,2.20,40238,DB00848,Levamisole
,27474036,tmax,The tmax was delayed for levamisole (2.20 ± 0.45 h) and abamectin (4.20 ± 1.64 days) compared with those in published studies.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),d,4.20,40239,DB00848,Levamisole
,27474036,MRT,Longer MRT values for levamisole (6.14 ± 1.14 h) and abamectin (8.80 ± 1.39 days) were found in this study compared to those reported.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),h,6.14,40240,DB00848,Levamisole
,27474036,MRT,Longer MRT values for levamisole (6.14 ± 1.14 h) and abamectin (8.80 ± 1.39 days) were found in this study compared to those reported.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),d,8.80,40241,DB00848,Levamisole
,12030791,alpha,"After compartmental analysis, the disposition of levamisole was well described by a two-compartment open model with mean values +/- sd of: alpha= 0.1650 +/- 0.0839, 0.1611 +/- 0.0298, 0.2312 +/- 0.0540 min (-1), and beta= 0.0118 +/- 0.0022, 0.0125 +/- 0.0026, 0.0120 +/- 0.0024 min (-1), for the three doses studied, respectively.",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min,0.1650,53762,DB00848,Levamisole
,12030791,alpha,"After compartmental analysis, the disposition of levamisole was well described by a two-compartment open model with mean values +/- sd of: alpha= 0.1650 +/- 0.0839, 0.1611 +/- 0.0298, 0.2312 +/- 0.0540 min (-1), and beta= 0.0118 +/- 0.0022, 0.0125 +/- 0.0026, 0.0120 +/- 0.0024 min (-1), for the three doses studied, respectively.",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min,0.1611,53763,DB00848,Levamisole
,12030791,alpha,"After compartmental analysis, the disposition of levamisole was well described by a two-compartment open model with mean values +/- sd of: alpha= 0.1650 +/- 0.0839, 0.1611 +/- 0.0298, 0.2312 +/- 0.0540 min (-1), and beta= 0.0118 +/- 0.0022, 0.0125 +/- 0.0026, 0.0120 +/- 0.0024 min (-1), for the three doses studied, respectively.",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min,0.2312,53764,DB00848,Levamisole
,12030791,beta,"After compartmental analysis, the disposition of levamisole was well described by a two-compartment open model with mean values +/- sd of: alpha= 0.1650 +/- 0.0839, 0.1611 +/- 0.0298, 0.2312 +/- 0.0540 min (-1), and beta= 0.0118 +/- 0.0022, 0.0125 +/- 0.0026, 0.0120 +/- 0.0024 min (-1), for the three doses studied, respectively.",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min,0.0118,53765,DB00848,Levamisole
,12030791,beta,"After compartmental analysis, the disposition of levamisole was well described by a two-compartment open model with mean values +/- sd of: alpha= 0.1650 +/- 0.0839, 0.1611 +/- 0.0298, 0.2312 +/- 0.0540 min (-1), and beta= 0.0118 +/- 0.0022, 0.0125 +/- 0.0026, 0.0120 +/- 0.0024 min (-1), for the three doses studied, respectively.",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min,0.0125,53766,DB00848,Levamisole
,12030791,beta,"After compartmental analysis, the disposition of levamisole was well described by a two-compartment open model with mean values +/- sd of: alpha= 0.1650 +/- 0.0839, 0.1611 +/- 0.0298, 0.2312 +/- 0.0540 min (-1), and beta= 0.0118 +/- 0.0022, 0.0125 +/- 0.0026, 0.0120 +/- 0.0024 min (-1), for the three doses studied, respectively.",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min,0.0120,53767,DB00848,Levamisole
,12030791,AUC,"The AUC increased significantly with the doses (249.7, 376.7 and 562.5 microg min ml (-1)).",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min·ml·μg,249.7,53768,DB00848,Levamisole
,12030791,AUC,"The AUC increased significantly with the doses (249.7, 376.7 and 562.5 microg min ml (-1)).",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min·ml·μg,376.7,53769,DB00848,Levamisole
,12030791,AUC,"The AUC increased significantly with the doses (249.7, 376.7 and 562.5 microg min ml (-1)).",Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12030791/),-1·min·ml·μg,562.5,53770,DB00848,Levamisole
,23943850,area under the parasite clearance curves,"Circulating late-stage parasites measured as the median area under the parasite clearance curves were 2150 (interquartile range [IQR], 0-28 025) parasites/µL × hour in patients treated with levamisole and 5489 (IQR, 192-25 848) parasites/µL × hour in controls (P = .25).",Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23943850/),[parasites] / [h·μl],2150,64586,DB00848,Levamisole
,23943850,area under the parasite clearance curves,"Circulating late-stage parasites measured as the median area under the parasite clearance curves were 2150 (interquartile range [IQR], 0-28 025) parasites/µL × hour in patients treated with levamisole and 5489 (IQR, 192-25 848) parasites/µL × hour in controls (P = .25).",Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23943850/),[parasites] / [h·μl],5489,64587,DB00848,Levamisole
,23943850,time to normalization of,"The median time to normalization of plasma lactate (<2 mmol/L) was 24 (IQR, 12-30) hours with levamisole vs 28 (IQR, 12-36) hours without levamisole (P = .15).",Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23943850/),h,24,64588,DB00848,Levamisole
,23943850,time to normalization of,"The median time to normalization of plasma lactate (<2 mmol/L) was 24 (IQR, 12-30) hours with levamisole vs 28 (IQR, 12-36) hours without levamisole (P = .15).",Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23943850/),h,28,64589,DB00848,Levamisole
,21256094,flow rate,"Chromatographic separation was carried on an Agilent HC-C(8) column (150 mm × 4.6 mm, 5 μm) at 40°C, with a mobile phase consisting of acetonitrile-10 mM ammonium acetate (70:30, v/v), a flow rate of 0.5 mL/min and a total run time of 6 min.",A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256094/),[ml] / [min],0.5,87532,DB00848,Levamisole
,21256094,total run time,"Chromatographic separation was carried on an Agilent HC-C(8) column (150 mm × 4.6 mm, 5 μm) at 40°C, with a mobile phase consisting of acetonitrile-10 mM ammonium acetate (70:30, v/v), a flow rate of 0.5 mL/min and a total run time of 6 min.",A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256094/),min,6,87533,DB00848,Levamisole
,7089376,peak plasma concentrations,"Levamisole, at a dose rate of 7.5 mg/kg, produced mean peak plasma concentrations of 3.1, 0.7 and 0.8 microgram/ml in four sheep after administrations by the subcutaneous, oral and intraruminal routes respectively.",Pharmacokinetics of levamisole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7089376/),[μg] / [ml],3.1,112216,DB00848,Levamisole
,7089376,peak plasma concentrations,"Levamisole, at a dose rate of 7.5 mg/kg, produced mean peak plasma concentrations of 3.1, 0.7 and 0.8 microgram/ml in four sheep after administrations by the subcutaneous, oral and intraruminal routes respectively.",Pharmacokinetics of levamisole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7089376/),[μg] / [ml],0.7,112217,DB00848,Levamisole
,7089376,peak plasma concentrations,"Levamisole, at a dose rate of 7.5 mg/kg, produced mean peak plasma concentrations of 3.1, 0.7 and 0.8 microgram/ml in four sheep after administrations by the subcutaneous, oral and intraruminal routes respectively.",Pharmacokinetics of levamisole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7089376/),[μg] / [ml],0.8,112218,DB00848,Levamisole
,7089376,peak concentrations,"The mean peak concentrations in abomasal fluid were 33, 164 and 21 micrograms/ml respectively.",Pharmacokinetics of levamisole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7089376/),[μg] / [ml],33,112219,DB00848,Levamisole
,7089376,peak concentrations,"The mean peak concentrations in abomasal fluid were 33, 164 and 21 micrograms/ml respectively.",Pharmacokinetics of levamisole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7089376/),[μg] / [ml],164,112220,DB00848,Levamisole
,7089376,peak concentrations,"The mean peak concentrations in abomasal fluid were 33, 164 and 21 micrograms/ml respectively.",Pharmacokinetics of levamisole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7089376/),[μg] / [ml],21,112221,DB00848,Levamisole
,24574157,LODs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.85,112921,DB00848,Levamisole
,24574157,LODs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.09,112922,DB00848,Levamisole
,24574157,LODs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.34,112923,DB00848,Levamisole
,24574157,LOQs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.09,112924,DB00848,Levamisole
,24574157,LOQs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.34,112925,DB00848,Levamisole
,24574157,ka,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[1] / [h],1.2,112926,DB00848,Levamisole
,24574157,CL/F,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[l] / [h],52,112927,DB00848,Levamisole
,24574157,V/F,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),l,347,112928,DB00848,Levamisole
,24574157,f (renal),"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),,0.0005,112929,DB00848,Levamisole
,24574157,t ½,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),h,2.0,112930,DB00848,Levamisole
,24574157,AUC,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [h·ml],1923,112931,DB00848,Levamisole
,24574157,cmax,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],214,112932,DB00848,Levamisole
,24574157,tmax,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),h,1.98,112933,DB00848,Levamisole
,12761805,V(d),V(d) was 0.266 L/kg of ideal body weight and Cl was 1.21 L/h. kg of total weight following weekly doses.,A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761805/),[l] / [kg],0.266,115173,DB00848,Levamisole
,12761805,Cl,V(d) was 0.266 L/kg of ideal body weight and Cl was 1.21 L/h. kg of total weight following weekly doses.,A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761805/),[l] / [h·kg],1.21,115174,DB00848,Levamisole
,282444,peak levamisole plasma level,In man a single oral dose of 150 mg produces a peak levamisole plasma level of 0.5 microgram/ml after 2-4 hours.,Pharmacokinetics of levamisole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282444/),[μg] / [ml],0.5,118326,DB00848,Levamisole
,282444,Urinary,"Urinary and fecal excretion of radioactivity amounted to 60% and 4% respectively after 24 hours, with only small amounts of unchanged drug being excreted.",Pharmacokinetics of levamisole. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282444/),%,60,118327,DB00848,Levamisole
,282444,Urinary,"Urinary and fecal excretion of radioactivity amounted to 60% and 4% respectively after 24 hours, with only small amounts of unchanged drug being excreted.",Pharmacokinetics of levamisole. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282444/),%,4,118328,DB00848,Levamisole
,282444,excretion,"Urinary and fecal excretion of radioactivity amounted to 60% and 4% respectively after 24 hours, with only small amounts of unchanged drug being excreted.",Pharmacokinetics of levamisole. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282444/),%,60,118329,DB00848,Levamisole
,282444,excretion,"Urinary and fecal excretion of radioactivity amounted to 60% and 4% respectively after 24 hours, with only small amounts of unchanged drug being excreted.",Pharmacokinetics of levamisole. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282444/),%,4,118330,DB00848,Levamisole
,1573709,alpha,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),1/[min],0.1278,120844,DB00848,Levamisole
,1573709,alpha,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),1/[min],0.1019,120845,DB00848,Levamisole
,1573709,alpha,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),1/[min],0.1282,120846,DB00848,Levamisole
,1573709,beta,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),1/[min],0.0139,120847,DB00848,Levamisole
,1573709,beta,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),1/[min],0.0126,120848,DB00848,Levamisole
,1573709,beta,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),1/[min],0.0124,120849,DB00848,Levamisole
,1573709,A,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[μg] / [ml],6.24,120850,DB00848,Levamisole
,1573709,A,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[μg] / [ml],5.27,120851,DB00848,Levamisole
,1573709,A,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[μg] / [ml],10.58,120852,DB00848,Levamisole
,1573709,A,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[μg] / [ml],2.14,120853,DB00848,Levamisole
,1573709,A,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[μg] / [ml],3.83,120854,DB00848,Levamisole
,1573709,B,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[μg] / [ml],2.14,120855,DB00848,Levamisole
,1573709,B,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[μg] / [ml],3.83,120856,DB00848,Levamisole
,1573709,B,"Using compartmental analysis, the disposition of levamisole best fitted a two-compartmental open model with mean values of alpha = 0.1278, 0.1019 and 0.1282 min-1; beta = 0.0139, 0.0126 and 0.0124 min-1; A = 6.24, 5.27 and 10.58 micrograms/ml and B = 2.14, 3.83 and 5.08 micrograms/ml for each dose, respectively.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[μg] / [ml],5.08,120857,DB00848,Levamisole
,1573709,mean residence time (MRT),"Values for mean residence time (MRT) of 69.2, 71.7 and 73.1 min were obtained for each dose.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),min,69.2,120858,DB00848,Levamisole
,1573709,mean residence time (MRT),"Values for mean residence time (MRT) of 69.2, 71.7 and 73.1 min were obtained for each dose.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),min,71.7,120859,DB00848,Levamisole
,1573709,mean residence time (MRT),"Values for mean residence time (MRT) of 69.2, 71.7 and 73.1 min were obtained for each dose.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),min,73.1,120860,DB00848,Levamisole
,1573709,volume of distribution at steady state (Vd(ss)),"The mean values for volume of distribution at steady state (Vd(ss)), determined by compartmental analysis, were 3879, 3279 and 2735 ml/kg for each dose, and values obtained using the statistical moment theory were 3760, 3015 and 2943 ml/kg; there were no statistically significant differences using Student's paired t-test.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[ml] / [kg],3879,120861,DB00848,Levamisole
,1573709,volume of distribution at steady state (Vd(ss)),"The mean values for volume of distribution at steady state (Vd(ss)), determined by compartmental analysis, were 3879, 3279 and 2735 ml/kg for each dose, and values obtained using the statistical moment theory were 3760, 3015 and 2943 ml/kg; there were no statistically significant differences using Student's paired t-test.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[ml] / [kg],3279,120862,DB00848,Levamisole
,1573709,volume of distribution at steady state (Vd(ss)),"The mean values for volume of distribution at steady state (Vd(ss)), determined by compartmental analysis, were 3879, 3279 and 2735 ml/kg for each dose, and values obtained using the statistical moment theory were 3760, 3015 and 2943 ml/kg; there were no statistically significant differences using Student's paired t-test.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[ml] / [kg],2735,120863,DB00848,Levamisole
,1573709,volume of distribution at steady state (Vd(ss)),"The mean values for volume of distribution at steady state (Vd(ss)), determined by compartmental analysis, were 3879, 3279 and 2735 ml/kg for each dose, and values obtained using the statistical moment theory were 3760, 3015 and 2943 ml/kg; there were no statistically significant differences using Student's paired t-test.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[ml] / [kg],3760,120864,DB00848,Levamisole
,1573709,volume of distribution at steady state (Vd(ss)),"The mean values for volume of distribution at steady state (Vd(ss)), determined by compartmental analysis, were 3879, 3279 and 2735 ml/kg for each dose, and values obtained using the statistical moment theory were 3760, 3015 and 2943 ml/kg; there were no statistically significant differences using Student's paired t-test.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[ml] / [kg],3015,120865,DB00848,Levamisole
,1573709,volume of distribution at steady state (Vd(ss)),"The mean values for volume of distribution at steady state (Vd(ss)), determined by compartmental analysis, were 3879, 3279 and 2735 ml/kg for each dose, and values obtained using the statistical moment theory were 3760, 3015 and 2943 ml/kg; there were no statistically significant differences using Student's paired t-test.",Pharmacokinetics of levamisole in rabbits after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573709/),[ml] / [kg],2943,120866,DB00848,Levamisole
,3754161,sensitivity,The sensitivity of the assay was 10 ng ml-1 and as low as 2 ng ml-1 can be detected in plasma.,Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754161/),[ng] / [ml],10,122962,DB00848,Levamisole
,3754161,sensitivity,The sensitivity of the assay was 10 ng ml-1 and as low as 2 ng ml-1 can be detected in plasma.,Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754161/),[ng] / [ml],2,122963,DB00848,Levamisole
,3754161,sensitivity,The sensitivity of this assay was 0.50 micrograms ml-1.,Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754161/),[μg] / [ml],0.50,122964,DB00848,Levamisole
,3754161,tmax,"Levamisole was rapidly absorbed (tmax 1.5 h), giving a peak plasma concentration of 716.7 +/- 217.5 ng ml-1.",Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754161/),h,1.5,122965,DB00848,Levamisole
,3754161,peak plasma concentration,"Levamisole was rapidly absorbed (tmax 1.5 h), giving a peak plasma concentration of 716.7 +/- 217.5 ng ml-1.",Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754161/),[ng] / [ml],716.7,122966,DB00848,Levamisole
,3754161,plasma elimination half-life,The plasma elimination half-life of levamisole was 5.6 +/- 2.5 h.,Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754161/),h,5.6,122967,DB00848,Levamisole
,3754161,Cumulative recovery,"Cumulative recovery of the metabolite accounted for 1.6 +/- 1.1 per cent and 12.4 +/- 5.5 per cent of the oral dose of levamisole before and after hydrolysis, respectively, indicating that p-hydroxylation is a relatively important route of metabolism of levamisole, and that the p-hydroxylated metabolite is excreted mainly in conjugation with glucuronic acid.",Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754161/),%,1.6,122968,DB00848,Levamisole
,3754161,Cumulative recovery,"Cumulative recovery of the metabolite accounted for 1.6 +/- 1.1 per cent and 12.4 +/- 5.5 per cent of the oral dose of levamisole before and after hydrolysis, respectively, indicating that p-hydroxylation is a relatively important route of metabolism of levamisole, and that the p-hydroxylated metabolite is excreted mainly in conjugation with glucuronic acid.",Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754161/),%,12.4,122969,DB00848,Levamisole
,6869955,Biological half-lives for elimination,"Biological half-lives for elimination of the drug were 9.3 and 6.9 hours after oral and IM administration, respectively.",Pharmacokinetics of [3H]levamisole in pigs after oral and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869955/),h,9.3,146631,DB00848,Levamisole
,6869955,Biological half-lives for elimination,"Biological half-lives for elimination of the drug were 9.3 and 6.9 hours after oral and IM administration, respectively.",Pharmacokinetics of [3H]levamisole in pigs after oral and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869955/),h,6.9,146632,DB00848,Levamisole
,6869955,Biliary excretion,"Biliary excretion of radioactivity and unchanged levamisole represented only slight percentages of the administered dose (approx 0.4% and 4.2%, respectively, in 72 hours).",Pharmacokinetics of [3H]levamisole in pigs after oral and intramuscular administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869955/),%,0.4,146633,DB00848,Levamisole
,6869955,Biliary excretion,"Biliary excretion of radioactivity and unchanged levamisole represented only slight percentages of the administered dose (approx 0.4% and 4.2%, respectively, in 72 hours).",Pharmacokinetics of [3H]levamisole in pigs after oral and intramuscular administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869955/),%,4.2,146634,DB00848,Levamisole
,32201965,terminal half-life,"The mean terminal half-life was 4.56, 3.95, and 2.91 hr for IM, gavage and feed routes, respectively.",Pharmacokinetics of levamisole after intramuscular and oral administrations to Caspian salmon (Salmo trutta caspius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201965/),h,4.56,147543,DB00848,Levamisole
,32201965,terminal half-life,"The mean terminal half-life was 4.56, 3.95, and 2.91 hr for IM, gavage and feed routes, respectively.",Pharmacokinetics of levamisole after intramuscular and oral administrations to Caspian salmon (Salmo trutta caspius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201965/),h,3.95,147544,DB00848,Levamisole
,32201965,terminal half-life,"The mean terminal half-life was 4.56, 3.95, and 2.91 hr for IM, gavage and feed routes, respectively.",Pharmacokinetics of levamisole after intramuscular and oral administrations to Caspian salmon (Salmo trutta caspius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201965/),h,2.91,147545,DB00848,Levamisole
,32201965,peak plasma concentration,"The peak plasma concentration for IM, gavage, and feed routes of levamisole were 35.53, 4.63, and 8.36 µg/ml, respectively, at the time of 0.25 for IM, and 1 hr for gavage and feed.",Pharmacokinetics of levamisole after intramuscular and oral administrations to Caspian salmon (Salmo trutta caspius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201965/),[μg] / [ml],35.53,147546,DB00848,Levamisole
,32201965,peak plasma concentration,"The peak plasma concentration for IM, gavage, and feed routes of levamisole were 35.53, 4.63, and 8.36 µg/ml, respectively, at the time of 0.25 for IM, and 1 hr for gavage and feed.",Pharmacokinetics of levamisole after intramuscular and oral administrations to Caspian salmon (Salmo trutta caspius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201965/),[μg] / [ml],4.63,147547,DB00848,Levamisole
,32201965,peak plasma concentration,"The peak plasma concentration for IM, gavage, and feed routes of levamisole were 35.53, 4.63, and 8.36 µg/ml, respectively, at the time of 0.25 for IM, and 1 hr for gavage and feed.",Pharmacokinetics of levamisole after intramuscular and oral administrations to Caspian salmon (Salmo trutta caspius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201965/),[μg] / [ml],8.36,147548,DB00848,Levamisole
,32201965,relative bioavailability,The relative bioavailability for gavage and feed routes was 54.80 and 69.30.,Pharmacokinetics of levamisole after intramuscular and oral administrations to Caspian salmon (Salmo trutta caspius). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201965/),,54.80,147549,DB00848,Levamisole
,32201965,relative bioavailability,The relative bioavailability for gavage and feed routes was 54.80 and 69.30.,Pharmacokinetics of levamisole after intramuscular and oral administrations to Caspian salmon (Salmo trutta caspius). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201965/),,69.30,147550,DB00848,Levamisole
,25677380,apparent clearance rate (CL/F),"The apparent clearance rate (CL/F) and distribution volume (V/F) were 44 l h(-1) 70 kg(-1) and 236 l 70 kg(-1) , respectively; estimated interindividual variability was 32-42%.",Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677380/),[l] / [70·h·kg],44,163683,DB00848,Levamisole
,25677380,distribution volume (V/F),"The apparent clearance rate (CL/F) and distribution volume (V/F) were 44 l h(-1) 70 kg(-1) and 236 l 70 kg(-1) , respectively; estimated interindividual variability was 32-42%.",Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677380/),[l] / [70·kg],236,163684,DB00848,Levamisole
,25677380,maximum plasma concentration,"The median (interquartile range) maximum plasma concentration of levamisole was 438.3 (316.5-621.8) ng ml(-1) , and the median area under the concentration-time curve was 2847 (2267-3761) ng ml(-1) h.",Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677380/),[ng] / [ml],438.3,163685,DB00848,Levamisole
,25677380,area under the concentration-time curve,"The median (interquartile range) maximum plasma concentration of levamisole was 438.3 (316.5-621.8) ng ml(-1) , and the median area under the concentration-time curve was 2847 (2267-3761) ng ml(-1) h.",Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677380/),[h·ng] / [ml],2847,163686,DB00848,Levamisole
,25677380,tmax,"Median tmax and t½ values were 1.65 (1.32-2.0) h and 2.60 (2.06-3.65) h, respectively.",Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677380/),h,1.65,163687,DB00848,Levamisole
,25677380,t½,"Median tmax and t½ values were 1.65 (1.32-2.0) h and 2.60 (2.06-3.65) h, respectively.",Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677380/),h,2.60,163688,DB00848,Levamisole
,6608036,peak plasma level,The results indicated that single administration of levamisole (2.5 mg/kg) in healthy men can promote an increase of early E rosettes with mean peak plasma level of 0.8 micrograms.,Lymphocytes T and pharmacokinetics after a single oral dose of levamisole in healthy and cancer subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6608036/),μg,0.8,167503,DB00848,Levamisole
,9554592,MTD,The MTD of oral levamisole was 100 mg/m2 administered three times a day concurrently with 450 mg/m2 per day intravenous 5-FU for 5 consecutive days.,Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554592/),[mg] / [m2],100,172837,DB00848,Levamisole
,9554592,Peak plasma concentrations,Peak plasma concentrations of 1 microg/ml (range 0.6-1.3 microg/ml) were achieved 90 min (range 60-360 min) after an oral dose of 100 mg/m2 levamisole with a 3.5-fold accumulation noted following 4 days of administration.,Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554592/),[μg] / [ml],1,172838,DB00848,Levamisole
lower,32910097,ultrafiltration efficiency of,"The ultrafiltration efficiency of unbound concentrations in plasma was lower than 85% (58.9%) but stable, and, therefore, the observed concentration should be corrected.",Development and Validation of a Highly Sensitive Liquid Chromatography-Tandem Mass Spectrometry Technique to Determine Levamisole in Plasma and Saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32910097/),%,85,192142,DB00848,Levamisole
,8040933,Cmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),[μg] / [ml],3.54,196363,DB00848,Levamisole
,8040933,Cmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),[μg] / [ml],4.51,196364,DB00848,Levamisole
,8040933,Cmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),[μg] / [ml],5.39,196365,DB00848,Levamisole
,8040933,tmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),min,12.0,196366,DB00848,Levamisole
,8040933,tmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),min,22.0,196367,DB00848,Levamisole
,8040933,tmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),min,20.0,196368,DB00848,Levamisole
,8040933,Cmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),[μg] / [ml],0.71,196369,DB00848,Levamisole
,8040933,Cmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),[μg] / [ml],1.32,196370,DB00848,Levamisole
,8040933,Cmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),[μg] / [ml],1.77,196371,DB00848,Levamisole
,8040933,tmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),min,46.0,196372,DB00848,Levamisole
,8040933,tmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),min,96.0,196373,DB00848,Levamisole
,8040933,tmax,"After non-compartmental analysis the mean values obtained were: Cmax = 3.54, 4.51 and 5.39 micrograms/ml; tmax = 12.0, 22.0 and 20.0 min; F = 134.8, 105.4 and 124.1% after subcutaneous administration for each dose, respectively, and Cmax = 0.71, 1.32 and 1.77 micrograms/ml; tmax = 46.0, 96.0 and 84.0 min; F = 53.0, 62.0 and 80.7% after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),min,84.0,196374,DB00848,Levamisole
,8040933,ka,"The ka values were 0.321, 0.145 and 0.145 min-1 after subcutaneous administration and 0.054, 0.023 and 0.027 min-1 after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),1/[min],0.321,196375,DB00848,Levamisole
,8040933,ka,"The ka values were 0.321, 0.145 and 0.145 min-1 after subcutaneous administration and 0.054, 0.023 and 0.027 min-1 after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),1/[min],0.145,196376,DB00848,Levamisole
,8040933,ka,"The ka values were 0.321, 0.145 and 0.145 min-1 after subcutaneous administration and 0.054, 0.023 and 0.027 min-1 after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),1/[min],0.054,196377,DB00848,Levamisole
,8040933,ka,"The ka values were 0.321, 0.145 and 0.145 min-1 after subcutaneous administration and 0.054, 0.023 and 0.027 min-1 after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),1/[min],0.023,196378,DB00848,Levamisole
,8040933,ka,"The ka values were 0.321, 0.145 and 0.145 min-1 after subcutaneous administration and 0.054, 0.023 and 0.027 min-1 after oral administration.",Bioavailability of levamisole administered by subcutaneous and oral routes in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040933/),1/[min],0.027,196379,DB00848,Levamisole
,30933367,elimination half-life,"The mean elimination half-life was 5.00, 7.88, and 9.43 hr for IV, IM, and SC routes, respectively.",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),h,5.00,227980,DB00848,Levamisole
,30933367,elimination half-life,"The mean elimination half-life was 5.00, 7.88, and 9.43 hr for IV, IM, and SC routes, respectively.",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),h,7.88,227981,DB00848,Levamisole
,30933367,elimination half-life,"The mean elimination half-life was 5.00, 7.88, and 9.43 hr for IV, IM, and SC routes, respectively.",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),h,9.43,227982,DB00848,Levamisole
,30933367,total clearance,"The total clearance and volume of distribution at steady state for the IV route were 0.14 L hr-1 kg-1 and 0.81 L/kg, respectively.",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),[l] / [h·kg],0.14,227983,DB00848,Levamisole
,30933367,volume of distribution at steady state,"The total clearance and volume of distribution at steady state for the IV route were 0.14 L hr-1 kg-1 and 0.81 L/kg, respectively.",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),[l] / [kg],0.81,227984,DB00848,Levamisole
,30933367,peak plasma concentration,"For the IM and SC routes, the peak plasma concentration was 9.63 and 10.51 μg/ml, respectively, with 0.5 hr of Tmax .",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),[μg] / [ml],9.63,227985,DB00848,Levamisole
,30933367,peak plasma concentration,"For the IM and SC routes, the peak plasma concentration was 9.63 and 10.51 μg/ml, respectively, with 0.5 hr of Tmax .",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),[μg] / [ml],10.51,227986,DB00848,Levamisole
,30933367,Tmax,"For the IM and SC routes, the peak plasma concentration was 9.63 and 10.51 μg/ml, respectively, with 0.5 hr of Tmax .",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),h,0.5,227987,DB00848,Levamisole
,30933367,bioavailability,"The bioavailability was 93.03 and 115.25% for the IM and SC routes, respectively.",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),%,93.03,227988,DB00848,Levamisole
,30933367,bioavailability,"The bioavailability was 93.03 and 115.25% for the IM and SC routes, respectively.",Pharmacokinetics of levamisole in the red-eared slider turtles (Trachemys scripta elegans). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30933367/),%,115.25,227989,DB00848,Levamisole
,14596467,hepatic extraction ratio,"Mean hepatic extraction ratio ranged from -0.044 to 0.017 and from 0.020 to 0.081 when area under the plasma concentration-time curve values were obtained after compartmental or noncompartmental analysis, respectively.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),,0.020 to 0.081,241961,DB00848,Levamisole
,14596467,volume of distribution at steady state (Vss),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[l] / [kg],4.26,241962,DB00848,Levamisole
,14596467,volume of distribution at steady state (Vss),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[l] / [kg],4.33,241963,DB00848,Levamisole
,14596467,volume of distribution at steady state (Vss),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[l] / [kg],3.20,241964,DB00848,Levamisole
,14596467,total body clearance (CI),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[ml] / [kg·min],49.04,241965,DB00848,Levamisole
,14596467,total body clearance (CI),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[ml] / [kg·min],43.77,241966,DB00848,Levamisole
,14596467,total body clearance (CI),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[ml] / [kg·min],39.26,241967,DB00848,Levamisole
,14596467,half-life associated with beta-phase (t1/2beta),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),min,77.93,241968,DB00848,Levamisole
,14596467,half-life associated with beta-phase (t1/2beta),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),min,85.39,241969,DB00848,Levamisole
,14596467,half-life associated with beta-phase (t1/2beta),"Mean pharmacokinetic parameter values were as follows for each dose (12.5, 16, and 20 mg/kg, respectively): after levamisole administration via the marginal ear vein, volume of distribution at steady state (Vss) = 4.26, 4.33, and 3.20 L/kg; total body clearance (CI) = 49.04, 43.77, and 39.26 mL/kg x min; and half-life associated with beta-phase (t1/2beta) = 77.93, 85.39, and 69.79 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),min,69.79,241970,DB00848,Levamisole
,14596467,Vss,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[l] / [kg],4.38,241971,DB00848,Levamisole
,14596467,Vss,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[l] / [kg],2.85,241972,DB00848,Levamisole
,14596467,Vss,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[l] / [kg],2.97,241973,DB00848,Levamisole
,14596467,CI,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[ml] / [kg·min],48.14,241974,DB00848,Levamisole
,14596467,CI,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[ml] / [kg·min],42.40,241975,DB00848,Levamisole
,14596467,CI,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),[ml] / [kg·min],39.69,241976,DB00848,Levamisole
,14596467,t1/2b,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),min,101.9,241977,DB00848,Levamisole
,14596467,t1/2b,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),min,76.71,241978,DB00848,Levamisole
,14596467,t1/2b,"After levamisole administration via the jejunal vein, Vss = 4.38, 2.85, and 2.97 L/kg; CI = 48.14, 42.40, and 39.69 mL/kg x min; and t1/2b = 101.9, 76.71, and 76.13 minutes.",Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14596467/),min,76.13,241979,DB00848,Levamisole
,30198755,detection,"Estimated validation parameters were as follows: decision limit, 0.54 μg/kg; detection capability, 0.56 μg/kg; limit of detection, 0.04 μg/kg; limit of quantification, 0.15 μg/kg; accuracy (recovery), between 92.9 and 102.3%; precision (relative standard deviation), ≤4.62%; and within-laboratory precision (relative standard deviation), ≤5.19%.",Estimation of the Withdrawal Time of Levamisole in Eggs after Oral Administration to Laying Hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198755/),,0,244963,DB00848,Levamisole
,30198755,limit of detection,"Estimated validation parameters were as follows: decision limit, 0.54 μg/kg; detection capability, 0.56 μg/kg; limit of detection, 0.04 μg/kg; limit of quantification, 0.15 μg/kg; accuracy (recovery), between 92.9 and 102.3%; precision (relative standard deviation), ≤4.62%; and within-laboratory precision (relative standard deviation), ≤5.19%.",Estimation of the Withdrawal Time of Levamisole in Eggs after Oral Administration to Laying Hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198755/),[μg] / [kg],0.04,244964,DB00848,Levamisole
,30198755,elimination half-life,"Significant elimination occurred within 5 days after the cessation of treatment in all groups, with an elimination half-life of 1.3 days.",Estimation of the Withdrawal Time of Levamisole in Eggs after Oral Administration to Laying Hens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198755/),d,1.3,244965,DB00848,Levamisole
,30198755,withdrawal time,The longest withdrawal time for levamisole in eggs (14.9 days) was determined in a group treated with 25 mg of levamisole per kg of body weight for two consecutive days.,Estimation of the Withdrawal Time of Levamisole in Eggs after Oral Administration to Laying Hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198755/),d,14.9,244966,DB00848,Levamisole
,34174358,zeta potential,The microemulsion was physically stable with an average size of 19.3 ± 0.1 nm and zeta potential of -3.84 ± 0.05 mV.,"Design, optimization and evaluation of a microemulsion-based hydrogel with high malleability for enhanced transdermal delivery of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34174358/),mv,-3.84,252749,DB00848,Levamisole
,16420302,volume of distribution at steady state (V(ss)),"The mean values for volume of distribution at steady state (V(ss)), determined by compartmental analysis, were significantly different for prelay and peak of egg production (8.358 and 13.581 mL/kg), respectively.",Pharmacokinetics of levamisole in broiler breeder chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16420302/),[ml] / [kg],8.358,274109,DB00848,Levamisole
,16420302,volume of distribution at steady state (V(ss)),"The mean values for volume of distribution at steady state (V(ss)), determined by compartmental analysis, were significantly different for prelay and peak of egg production (8.358 and 13.581 mL/kg), respectively.",Pharmacokinetics of levamisole in broiler breeder chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16420302/),[ml] / [kg],13.581,274110,DB00848,Levamisole
